Murray Stahl's ABT Position Overview
Murray Stahl (via Horizon Kinetics Asset Management LLC) currently holds 10,051 shares of Abbott Laboratories (ABT) worth $1.26 M, representing 0.02% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 51 quarters.
Based on 13F filings since 2013, Murray Stahl has maintained a long-term strategic position in ABT, representing a significant commitment to this investment thesis. Largest addition occurred in Q3 2015, adding 2,900 shares. Largest reduction occurred in Q4 2014, reducing 7,830 shares.
Analysis based on 13F filings available since 2013 Q2
Murray Stahl's Abbott Laboratories (ABT) Holding Value Over Time
Track share changes against reported price movement
Quarterly Abbott Laboratories (ABT) Trades by Murray Stahl
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2013 | +36,004 | Add 0.00% | 36,003 | $34.89 |
| Q3 2013 | +735 | Add 2.04% | 36,738 | $33.18 |
| Q4 2013 | -2,135 | Reduce 5.81% | 34,603 | $38.32 |
| Q1 2014 | +300 | Add 0.87% | 34,903 | $38.51 |
| Q2 2014 | -600 | Reduce 1.72% | 34,303 | $40.90 |
| Q3 2014 | -5,000 | Reduce 14.58% | 29,303 | $41.60 |
| Q4 2014 | -7,830 | Reduce 26.72% | 21,473 | $45.03 |
| Q1 2015 | -2,870 | Reduce 13.37% | 18,603 | $46.34 |
| Q3 2015 | +2,900 | Add 15.59% | 21,503 | $40.23 |
| Q4 2015 | +1,000 | Add 4.65% | 22,503 | $44.93 |
| Q1 2016 | +275 | Add 1.22% | 22,778 | $41.84 |
| Q2 2016 | +200 | Add 0.88% | 22,978 | $39.30 |
| Q3 2016 | -350 | Reduce 1.52% | 22,628 | $42.29 |
| Q4 2016 | -100 | Reduce 0.44% | 22,528 | $38.40 |
| Q1 2017 | +1,200 | Add 5.33% | 23,728 | $44.42 |
| Q2 2017 | +747 | Add 3.15% | 24,475 | $48.62 |
| Q3 2017 | -1,247 | Reduce 5.09% | 23,228 | $53.34 |
| Q4 2017 | -200 | Reduce 0.86% | 23,028 | $57.06 |
| Q3 2018 | -700 | Reduce 3.04% | 22,328 | $73.36 |
| Q4 2018 | -44 | Reduce 0.20% | 22,284 | $72.34 |
| Q1 2019 | -800 | Reduce 3.59% | 21,484 | $79.92 |
| Q2 2019 | -1,046 | Reduce 4.87% | 20,438 | $84.11 |
| Q3 2019 | -100 | Reduce 0.49% | 20,338 | $83.69 |
| Q4 2019 | -330 | Reduce 1.62% | 20,008 | $86.87 |
| Q1 2020 | -553 | Reduce 2.76% | 19,455 | $78.90 |
| Q2 2020 | -3,370 | Reduce 17.32% | 16,085 | $91.45 |
| Q3 2020 | +475 | Add 2.95% | 16,560 | $108.82 |
| Q4 2020 | -644 | Reduce 3.89% | 15,916 | $109.51 |
| Q1 2021 | -550 | Reduce 3.46% | 15,366 | $119.81 |
| Q3 2021 | -450 | Reduce 2.93% | 14,916 | $118.13 |
| Q1 2023 | +18 | Add 0.12% | 14,934 | $101.26 |
| Q2 2023 | -4,468 | Reduce 29.92% | 10,466 | $109.02 |
| Q3 2023 | -100 | Reduce 0.96% | 10,366 | $96.85 |
| Q4 2023 | -175 | Reduce 1.69% | 10,191 | $110.07 |
| Q1 2024 | -100 | Reduce 0.98% | 10,091 | $113.66 |
| Q4 2024 | -50 | Reduce 0.50% | 10,041 | $113.11 |
| Q2 2025 | +418 | Add 4.16% | 10,459 | $136.01 |
| Q4 2025 | -408 | Reduce 3.90% | 10,051 | $125.29 |
Murray Stahl's Abbott Laboratories Investment FAQs
Murray Stahl first purchased Abbott Laboratories (ABT) in Q2 2013, acquiring 36,003 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Murray Stahl has held Abbott Laboratories (ABT) for 51 quarters since Q2 2013.
Murray Stahl's largest addition to Abbott Laboratories (ABT) was in Q2 2013, adding 36,003 shares worth $1.26 M.
According to the latest 13F filing for Q4 2025, Murray Stahl's firm, Horizon Kinetics Asset Management LLC, owns 10,051 shares of Abbott Laboratories (ABT), valued at approximately $1.26 M.
As of the Q4 2025 filing, Abbott Laboratories (ABT) represents approximately 0.02% of Murray Stahl's publicly disclosed stock portfolio, making it one of their key holdings.
Murray Stahl's peak holding in Abbott Laboratories (ABT) was 36,738 shares, as reported at the end of Q3 2013.